KalVista Pharmaceuticals (NASDAQ:KALV) PT Raised to $24.00 at HC Wainwright
KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) had its price target upped by HC Wainwright from $16.00 to $24.00 in a research note issued to investors on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the specialty pharmaceutical company’s stock. Separately, Needham & Company LLC lifted their price objective on shares of KalVista […]
More Stories
Trump Says US Negotiators Will Travel to Pakistan for Peace Talks With Iran
By Tom Gantert President Donald Trump said on Sunday that U.S. representatives will arrive in Pakistan on Monday evening in...
Six Dead After Shooter Opens Fire in Kyiv
By Jacki Thrapp At least six people died on April 18 when a man opened fire in Kyiv’s Holosiivskyi district....
USDA Disqualifies 1,562 Retailers, Prevents $835 Million in Fraudulent SNAP Transactions
By Naveen Athrappully The U.S. Department of Agriculture’s Food and Nutrition Service has disqualified 1,562 retailers associated with the Supplemental...
Abbott Threatens $200 Million in Funding Cuts Across Texas’s Largest Cities Over ICE Policies
By Kimberly Hayek Texas Gov. Greg Abbott on April 16 threatened to cut more than $200 million in public safety...
Wall Street Review: S&P 500 Surpasses 7,100 for First Time
By Panos Mourdoukoutas Stocks extended their rebound into the third week of April, with the S&P 500 and Nasdaq reaching...
Appeals Court Allows Construction of White House Ballroom to Continue
By Aldgra Fredly A U.S. appeals court on April 17 put on hold a lower court order that had halted...